MedPath

Study of Acute Autoimmune Encephalitis With Positive Antibodies in Eastern France

Completed
Conditions
Acute Autoimmune Encephalitis
Registration Number
NCT05605223
Lead Sponsor
University Hospital, Strasbourg, France
Brief Summary

The number of acute encephalitides diagnosed each year is gradually increasing, reaching approximately 5 to 10/100,000 per year; more than 50% of etiologies currently remain unknown. The majority of them are acute encephalitis of infectious origin, but it is estimated that 20% of encephalitis in northern Europe is related to an autoimmune mechanism with the majority of encephalitis with anti-NMDA Ac discovered recently in 2007. The study of a large American encephalitis cohort showed a death rate of 3% to 7% in cases of autoimmune encephalitis. Furthermore, delay in the initiation of effective treatment (tumor removal or immunotherapy) beyond 4 weeks is associated with a poor prognosis at 1 year.

It is therefore necessary to better understand the signs of autoimmune encephalitis in order to recognize the disease quickly and to start a treatment quickly; in order to improve the management and the prognosis of these children.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
50
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Retrospective description of autoimmune encephalitis in childrenFiles analysed retrospectively from January 01, 2006 to December 31, 2018 will be examined
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Service de Pédiatrie 1 - CHU de Strasbourg - France

🇫🇷

Strasbourg, France

Service de Pédiatrie 1 - CHU de Strasbourg - France
🇫🇷Strasbourg, France

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.